Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 September 2020Website:
http://www.athira.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ATHA Latest News
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that its Director Geodata Drew Heasman, who leads its Digital Discovery team, has been awarded the top prize at the 2023/2024 Future Explorer's Competition. Organized by Humyn AI and funded by Dundee Precious Metals, the Future Explorer's Competition began in November 2023 and brings together more than 200 data scientists and geoscientists from 37 countries.
SEATTLE , June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al.
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has commenced Phase I of its 2024 Angilak Diamond Drilling Exploration Program at its Angilak Project in Nunavut. The program involves around 10,000 meters of diamond drilling, targeting the expansion of high-grade uranium mineralization at the Lac 50 Deposit and adjacent zones.
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has signed an option agreement with Riverboat Energy Corporation, granting Riverboat the exclusive option to acquire a 70% interest in ATHA's Vista property in the Athabasca Basin. The agreement, effective May 20, 2024, allows Riverboat to earn the interest by fulfilling specified cash payments, share issuances, and exploration expenditures on the Vista property.
Athira Pharma, Inc. announced that a proposed settlement for the claims against individual defendants in stockholder derivative actions has been preliminarily approved by the U.S. District Court for the Western District of Washington. The settlement includes corporate governance reforms and payments for attorney's fees, expenses, and service awards to lead plaintiffs.
Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in the following upcoming investor conferences:
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What type of business is Athira Pharma?
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
What sector is Athira Pharma in?
Athira Pharma is in the Healthcare sector
What industry is Athira Pharma in?
Athira Pharma is in the Biotechnology industry
What country is Athira Pharma from?
Athira Pharma is headquartered in United States
When did Athira Pharma go public?
Athira Pharma initial public offering (IPO) was on 18 September 2020
What is Athira Pharma website?
https://www.athira.com
Is Athira Pharma in the S&P 500?
No, Athira Pharma is not included in the S&P 500 index
Is Athira Pharma in the NASDAQ 100?
No, Athira Pharma is not included in the NASDAQ 100 index
Is Athira Pharma in the Dow Jones?
No, Athira Pharma is not included in the Dow Jones index
When does Athira Pharma report earnings?
The next expected earnings date for Athira Pharma is 09 August 2024